Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc V.LXG


Primary Symbol: LXXGQ

Healthcare Medical Devices
Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Lexagene Holdings Inc > new video on twitter 56 mins ago
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(18)
•••
Comment by Investor62on Apr 15, 2020 9:38am
60 Views
Post# 30911068

RE:RE:RE:RE:RE:RE:RE:RE:RE:new video on twitter 56 mins ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:new video on twitter 56 mins agoIntelligent??
did you read what you sent to the last lines?

However, an ideal test would analyze blood samples instead of saliva, which is more accurate as it’s less likely to miss the virus. Also, a blood test can measure a patient’s immune response to COVID-19 to see if they’ve built up resistance to future infections — something the new Rutgers test can’t do.

But in the absence of widely-distributed blood tests, the merits of a saliva test over nasal swabs stand to benefit lots of people — and could help the country get a better grip on this outbreak.

Definitely no competition for what Lexagene is doing. Just to make the president happy

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities